IR-Med Inc., a development stage medical device company, focuses on the development of infra-red light spectroscopy combined with artificial intelligence technology platform to address diagnostic o...
Most recently: Entry into a Material Definitive Agreement. On February 4, 2026, IR-Med, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agree (2026-02-05).
—
Market Cap
—
Revenue
—
Net Income
IR-Med Inc., a development stage medical device company, focuses on the development of infra-red light spectroscopy combined with artificial intelligence technology platform to address diagnostic or medical needs. It is developing PressureSafe, a handheld optical monitoring device to support early detection of pressure injuries to the skin and underlying tissue primarily caused by prolonged pressure associated with bed confinement; and Nobiotics, an otoscope to support physicians with an immediate indication as to whether mid-ear infection (Otitis Media), a common malady in children. The company is headquartered in Rosh Pina, Israel.